Delivery Order SPE2DB24D9144-SPE2DB25FCMYK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a specific fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. No...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on July 22, 2025, is expected to be completed by July 23, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules in quantities of 120 units. This $17,245.40 firm fixed-price delivery order was awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, and carries no set-aside designation. The order falls under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120 count). The contract, awarded on July 23, 2025, with a completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single-transaction fulfillment of pharmaceutical inventory...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract, valued at $12,934.05, to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 40 mg capsules. DMS Pharmaceutical Group holds an Indefinite Delivery Vehicle (IDV) contract, valued up to $4,999,999, with DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a broad range of pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $10,222.72, is scheduled for completion by July 31, 2025, and was issued on July 30, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. This...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of 120 count bottles of the prescription drug Xtandi 40 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $32,873.49 contract is for the delivery of 120-count capsules of the prescription drug Xtandi 40 mg. This delivery order contract is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which allows the DLA...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $43,113.50 by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract employs firm fixed-price pricing and is not designated as a set-aside award. Performance will be completed by July 31, 2025, with delivery to Park Ridge, Illinois. This delivery order is issued under DMS...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCMYKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (quantity: 120 units). This firm fixed-price delivery order, valued at $4,311.35, was awarded on August 20, 2025, with an ultimate completion date of August 21, 2025. The contract carries no set-aside designation, demonstrating the contractor's competitive positioning in federal pharmaceutical procurement. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.9 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military healthcare facilities worldwide. DMS Pharmaceutical Group serves as a critical supplier within the Department of Defense's pharmaceutical supply chain, specializing in the distribution of branded and generic prescription medications, biologics, and medical consumables to federal healthcare systems. The contractor's portfolio encompasses oncology treatments, specialty injections, and other critical pharmaceutical products essential to military medical operations. By leveraging its woman-owned small business status, DMS Pharmaceutical Group has maintained a robust federal contract award history with the DLA, securing multiple delivery orders across diverse pharmaceutical categories without set-aside restrictions, positioning it as a preferred vendor for direct pharmaceutical distribution to DoD healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 8/20/25 |